// App-Quantinova.ai

INFO07 : Design of the CALCIPHYX Study, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SNF472 for Treating Calciphylaxis

Researchers

Presenter

  • Sinha Smeeta

Principal Investigators

  • Gould Lisa

  • Nigwekar SagarU

  • Moe SharonM

  • Aronoff GeorgeR

  • Hymes JeffreyL

  • Miller Stephan

  • Padgett ClaireS

  • Gold Alex

  • Perell Joan

  • Chertow GlennMatthew

Medical Centers

  • Salford Royal NHS Foundation Trust and The University of Manchester Greater Manchester United Kingdom

  • South Shore Hospital Center for Wound Healing, Weymouth, Massachusetts, United States

  • Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States

  • IU School of Medicine, Indianapolis, Indiana, United States

  • DaVita Kidney Care Naples Florida United States

  • Fresenius Kidney Care Nashville Tennessee United States

  • del mar, Sanifit Therapeutics, Palma, Spain

  • Stanford University Medical Center, Stanford, California, United States

Locations

  • United Kingdom

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Calciphylaxis

  • Calcified vascular disease

Biomarkers

  • N/A

Drug/Treatment

  • Inositol

  • Hexasodium phytate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved